4results about How to "Reduce weight ratio" patented technology

The invention discloses application of hydrotalcite and an ursodesoxycholic acid oral suspension composition, a suspension is composed of two parts, namely a drug-loaded pellet and an inactive particle, the drug-loaded pellet is composed of a drug-loaded pellet core and a taste-masking coating layer, and the taste-masking coating layer comprises zein, hydrotalcite, an anti-sticking agent and a plasticizer; the inactive particles comprise a filling agent, a suspending aid and essence. The drug-loaded pellet of the ursodesoxycholic acid oral suspension composition is composed of a drug-loaded pellet core and a taste-masking coating layer, ursodesoxycholic acid is contained in the drug-loaded pellet core, and hydrotalcite serving as a pore-foaming agent is contained in the taste-masking coating layer. Therefore, when the composition medicine is taken, whether the film-forming material zein or the pore-foaming agent is not dissolved in water during taking, and after the composition medicine reaches the stomach, hydrotalcite can generate neutralization reaction with gastric acid to play a role of the pore-foaming agent, so that quick release of the composition medicine is ensured.

The utility model discloses an electric power tower carbon fiber reinforcing structure which comprises an iron stand, needing to be reinforced, of an electric power tower, a carbon fiber reinforcing piece is attached to the outer side of the iron stand, a plurality of sets of locking pieces are connected to the outer side of the iron stand and the outer side of the carbon fiber reinforcing piece in a clamped mode, each locking piece comprises a buckle and a fastening bolt, and a through hole is formed in the outer side of each buckle. According to the utility model, the carbon fiber reinforcing member is attached to the iron stand for installation, the iron stand is supported by using the strength and the bending resistance of the carbon fiber reinforcing member, and then the carbon fiber reinforcing member and the iron stand are fixed by using the locking member, so that the carbon fiber reinforcing member and the iron stand are fixed together. According to the method, stable supporting of the carbon fiber reinforcing part to the iron frame is guaranteed, expansion of fatigue cracks is delayed, the rigidity and bearing capacity of an original structure can be effectively improved on the basis of defects of a traditional reinforcing method, meanwhile, compared with a traditional metal reinforcing part, the carbon fiber reinforcing part is reduced in weight proportion, and the load of the electric power tower is reduced.

The utility model relates to the technical field of lithium ion battery especially, it relates to current collector and negative pole piece. The current collector in the negative pole piece includes foil, first structural layer and second structural layer, the foil is provided with first through -hole, first structural layer is provided with second through -hole, the both ends fixed with foil of first structural layer along the thickness direction, the projection of first through -hole and second through -hole along the thickness direction coincides, first through -hole and second through -hole constitute the through -cavity for accommodating slurry, second structural layer is fixed on any one of two foils, second structural layer is fixed on the end face of corresponding foil away from first structural layer along the thickness direction, second structural layer blocks first through -hole, the foil without fixed second structural layer has first coating surface away from first structural layer along the thickness direction, the foil with fixed second structural layer has second coating surface close to second structural layer along the thickness direction, and first coating surface and second coating surface carry out coating processing in proper order.

The present invention discloses the use of a dual inhibitor YS-121 in the preparation of a drug for preventing and / or treating polycystic kidney disease. The dual inhibitor YS-121 has a structure as shown in the following formula: wherein the pharmaceutically acceptable derivative is selected from at least one of a pharmaceutically acceptable salt, a polymorph, a co-crystal, a radiolabeled form and a combination thereof. The present invention reports for the first time the use of YS-121 in the treatment and / or prevention of autosomal dominant polycystic kidney disease. Experiments have shown that the administration of a drug containing YS-121 can significantly reduce the kidney-to-body weight ratio of polycystic kidney individuals by inhibiting the proliferation of renal tubular epithelial cells, significantly reduce the morphological damage of renal tissue in polycystic kidney individuals, and significantly improve the size of cell vesicles in vitro, which has an improvement effect on autosomal dominant polycystic kidney disease, and provides valuable reference significance for the prevention and treatment of polycystic kidney disease in clinical practice.